# Checkmate Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/checkmate-pharmaceuticals

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.checkmatepharma.com
- Total disclosed funding: $144M
- Latest round: Series C (Jun 8, 2020)
- Investors on record: 11

## About

Checkmate Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative treatments to enhance cancer immunotherapy and address unmet medical needs.Founded in 2015 and headquartered in Cambridge, US, Checkmate Pharmaceuticals, Inc. specializes in immuno-oncology. The company has undergone significant strategic development, including its acquisition by Regeneron Pharmaceuticals, Inc. in May 2022, with the deal valuing Checkmate at approximately USD 250 million. The company has successfully completed 9 deals and raised a total of USD 75.00 mn through its IPO in August 2020, which involved selling 5.0 million shares at USD 15 per share. The CEO is Barry Labinger, while the founder is Arthur Krieg, who has been involved in other ventures in the biotechnology sector.Checkmate Pharmaceuticals, Inc. develops innovative therapies focused on enhancing the immune system's ability to fight cancer, particularly through its proprietary technology and platform for immuno-oncology. Its product pipeline includes investigational therapies aimed at improving patient outcomes in cancer treatment.In 2021, Checkmate Pharmaceuticals, Inc. reported an EBITDA of USD -60.71 mn, indicating the company's ongoing investments in research and development as it advances its product offerings.Checkmate Pharmaceuticals, Inc. plans to utilize the recent funding raised in its IPO to further develop its product pipeline and expand its market presence. The company is focused on launching new immuno-oncology therapies and aims to penetrate additional markets in North America and Europe by 2025. With the backing of Regeneron Pharmaceuticals, Inc., Checkmate is positioned to enhance its research capabilities and accelerate the pace of innovation in cancer treatment.

## Funding rounds

- Series C, Jun 8, 2020, $85M — Sofinnova Investments, Novo Holdings, F-Prime Capital, Longitude Capital, Omega Funds, Sectoral Asset Management, Decheng Capital, VenBio, Clough Capital Partners, Medicxi, BrightEdge Ventures
- Series B, Dec 12, 2018, $22M — Sofinnova Investments, F-Prime Capital, Decheng Capital, VenBio
- Series B, Jun 2, 2017, $27M — Sofinnova Investments, F-Prime Capital, VenBio
- Series A, Aug 11, 2015, $10M — Sofinnova Investments, VenBio

## Investors

- Sofinnova Investments (https://capitalatlas.ai/funds/sofinnova-investments) — Series A, Series B, Series C
- VenBio (https://capitalatlas.ai/funds/venbio) — Series A, Series B, Series C
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series B, Series C
- Decheng Capital (https://capitalatlas.ai/funds/decheng-capital) — Series B, Series C
- Novo Holdings — Series C
- Longitude Capital (https://capitalatlas.ai/funds/longitude-capital) — Series C
- Omega Funds (https://capitalatlas.ai/funds/omega-funds) — Series C
- Sectoral Asset Management (https://capitalatlas.ai/funds/sectoral-asset-management) — Series C
- Clough Capital Partners — Series C
- Medicxi (https://capitalatlas.ai/funds/medicxi) — Series C
- BrightEdge Ventures (https://capitalatlas.ai/funds/brightedge-ventures) — Series C